Patents by Inventor Gunther Zischinsky
Gunther Zischinsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945822Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: GrantFiled: April 11, 2019Date of Patent: April 2, 2024Assignees: QURIENT CO., LTD., LEAD DISCOVERY CENTER GMBHInventors: Kiyean Nam, Jaeseung Kim, Yeejin Jeon, Donghoon Yu, Mooyoung Seo, Dongsik Park, Jan Eickhoff, Gunther Zischinsky
-
Patent number: 11858937Abstract: The present invention relates to pyrazolo [1,5-a][1,3,5]triazine and pyrazolo [1,5-a]pyrimidine derivatives having Formula I: and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: GrantFiled: April 11, 2019Date of Patent: January 2, 2024Assignees: QURIENT CO., LTD., LEAD DISCOVERY CENTER GMBHInventors: Kiyean Nam, Jaeseung Kim, Yeejin Jeon, Donghoon Yu, Mooyoung Seo, Dongsik Park, Jan Eickhoff, Gunther Zischinsky, Uwe Koch
-
Publication number: 20220098208Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: December 13, 2021Publication date: March 31, 2022Inventors: KIYEAN NAM, JAESEUNG KIM, YEEJIN JEON, DONGHOON YU, MOOYOUNG SEO, DONGSIK PARK, JAN EICKHOFF, GUNTHER ZISCHINSKY, UWE KOCH
-
Publication number: 20210198269Abstract: The present invention relates to 2,6-methanobenzo[g][l]oxacin-4-onecompounds and their analog compounds and pharmaceutically acceptable salts thereof as selective inhibitor of glucose transporters 1 and 3 (GLUTs 1 and 3), to methods of preparing said compounds, and to the use thereof as pharmaceutically active agents, especially for the prophylaxis and/or treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis thereof. Furthermore, the present invention is directed to pharmaceutical composition comprising at least one of 2,6-methanobenzo[g][l]oxacin-4-one compounds and their analog compounds.Type: ApplicationFiled: September 5, 2019Publication date: July 1, 2021Inventors: Herbert Waldmann, Gunther Zischinsky, Peter Nussbaumer, Slava Ziegler, Melanie Schwalfenberg, Javier de Ceballos Cerrajeria, Elena Sabrina Reckzeh, George Karageorgis
-
Publication number: 20210147427Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 11, 2019Publication date: May 20, 2021Inventors: KIYEAN NAM, JAESEUNG KIM, YEEJIN JEON, DONGHOON YU, MOOYOUNG SEO, DONGSIK PARK, JAN EICKHOFF, GUNTHER ZISCHINSKY
-
Publication number: 20210139483Abstract: The present invention relates to pyrazolo [1,5-a] [1,3,5]triazine and pyrazolo[1,5-a] pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo [1,5-a][1,3,5]triazine and pyrazolo [1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 11, 2019Publication date: May 13, 2021Inventors: KIYEAN NAM, JAESEUNG KIM, YEEJIN JEON, DONGHOON YU, MOOYOUNG SEO, DONGSIK PARK, JAN EICKHOFF, GUNTHER ZISCHINSKY, UWE KOCH
-
Patent number: 9567345Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.Type: GrantFiled: March 1, 2013Date of Patent: February 14, 2017Assignee: Lead Discovery Center GmbHInventors: Jan Eickhoff, Gunther Zischinsky, Uwe Koch
-
Patent number: 9096608Abstract: Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.Type: GrantFiled: March 1, 2013Date of Patent: August 4, 2015Assignee: Lead Discovery Center GmbHInventors: Jan Eickhoff, Gunther Zischinsky, Uwe Koch, Gerd Rühter, Carsten Schultz-Fademrecht, Peter Nussbaumer
-
Publication number: 20150111873Abstract: Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.Type: ApplicationFiled: March 1, 2013Publication date: April 23, 2015Applicant: LEAD DISCOVERY CENTER GMBHInventors: Jan Eickhoff, Gunther Zischinsky, Uwe Koch, Gerd Rühter, Carsten Schultz-Fademrecht, Peter Nussbaumer
-
Publication number: 20150018329Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.Type: ApplicationFiled: March 1, 2013Publication date: January 15, 2015Applicant: LEAD DISCOVERY CENTER GMBHInventors: Jan Eickhoff, Gunther Zischinsky, Uwe Koch
-
Patent number: 8927534Abstract: The present invention is related to a compound of formula (I), wherein A is a nonaromatic heterocyclic ring, Ar is either absent or phenylene; ? is a radical of formula (II), R2 is a hydrophobic moiety; and G is a radical containing one or more moieties selected from the group consisting of NH, OH and a basic moiety. The compounds are inhibitors of integrins, especially antagonists of the fibronectin receptor alpha5beta1, useful as anti-angiogenic agents.Type: GrantFiled: January 31, 2007Date of Patent: January 6, 2015Assignee: Shire Orphan Therapies GmbHInventors: Gunther Zischinsky, Roland Stragies, Frank Osterkamp, Dirk Scharn, Gerd Hummel, Holger Kalkhof, Grit Zahn, Doerte Vossmeyer, Claudia Christner-Albrecht, Ulrich Reineke
-
Patent number: 8501787Abstract: This invention is directed to compounds of structure (I). Particularly this invention is directed to compounds of structure (VIII) wherein the variables are defined as in the description. These compounds are integrin inhibitors and are useful in the treatment of diseases in which an inhibition of angiogenesis is desired.Type: GrantFiled: March 24, 2005Date of Patent: August 6, 2013Assignee: Shire Orphan Therapies GmbHInventors: Grit Zahn, Roland Stragies, Frank Osterkamp, Gunther Zischinsky, Jochen Knolle, Gerd Hummel, Sascha Birkner, Ulrich Reineke
-
Patent number: 8309735Abstract: The present invention relates to compounds of formula (I) wherein: A is a radical selected from the group comprising aromatic heterocyclic 5-membered ring systems; Ar is a radical selected from the group comprising optionally substituted 5- and 6-membered aromatic ring systems, whereby the ring system contains 0, 1, 2 or 3 heteroatoms selected from the group comprising N, O and S; Z is a linker and ? is a radical of formula (II) and their use for the inhibition of integrin.Type: GrantFiled: May 14, 2007Date of Patent: November 13, 2012Assignee: Shire Orphan Therapies GmbHInventors: Gunther Zischinsky, Roland Stragies, Frank Osterkamp, Dirk Scharn, Gerd Hummel, Holger Kalkhof, Grit Zahn, Doerte Vossmeyer, Claudia Christner-Albrecht, Ulrich Reineke
-
Patent number: 7759302Abstract: The invention relates to novel peptides which are biologically active as ligands of blood platelet integrin GPIIbIIIa and the ?v integrins, preferably the av?s and ?v?3 integrin, having the formula (I): R1-Arg-X-Asp-Leu-Asp-Ser-Leu-Arg-R2 (I), in which R1 denotes H, acetyl or acyl and R2 denotes -Oh, OR3NH2, NHR3, N(R3)2 R3 denotes atkyl, aralkyl, aryl, Het and X denotes an amino acid of the formula (II), in which A denotes (CH2)n R4 denotes H, alkyl, aralkyl or aryl, and n denotes 1, 2, 3, 4, 5 or 6, and the amino acid of the formula (II) is bonded to the adjacent Arg via a peptide bond of the ?-amino group and to the ?-amino group of the adjacent Asp via a peptide bond of the ?-carboxyl group.Type: GrantFiled: January 14, 2004Date of Patent: July 20, 2010Assignee: Merck Patent GmbHInventors: Alfred Jonczyk, Ulrich Groth, Gunther Zischinsky
-
Publication number: 20090203745Abstract: The present invention relates to compounds of formula (I) wherein: A is a radical selected from the group comprising aromatic heterocyclic 5-membered ring systems; Ar is a radical selected from the group comprising optionally substituted 5- and 6-membered aromatic ring systems, whereby the ring system contains 0, 1, 2 or 3 heteroatoms selected from the group comprising N, O and S; Z is a linker and ? is a radical of formula (II) and their use for the inhibition of integrin.Type: ApplicationFiled: May 14, 2007Publication date: August 13, 2009Applicant: Jerini AGInventors: Gunther Zischinsky, Roland Stragies, Frank Osterkamp, Dirk Scharn, Gerd Hummel, Holger Kalkhof, Grit Zahn, Doerte Vossmeyer, Claudia Christner-Albrecht, Ulrich Reineke
-
Publication number: 20080194524Abstract: The present invention is related to compounds having formula (I) wherein the dashed line indicates a single or double bond or is absent and wherein A1-A9, Q, R1-R11, T, U, V, W1-W3, X1, X2, Y and Z are as defined in the claims and description, pharmaceutical compositions comprising the compounds and the use of the compounds for the manufacture of a medicament for the treatment of diseases involving abnormal cell proliferation, undesired cell proliferation, abnormal mitosis and/or undesired mitosis.Type: ApplicationFiled: December 18, 2004Publication date: August 14, 2008Applicant: JERINI AGInventors: Jochen Knolle, Mike Schutkowski, Gerd Hummel, Thomas Tradler, Laurence Jobron, Claudia Christner, Christoph Gibson, Gunther Zischinsky
-
Publication number: 20070155712Abstract: This invention is directed to compounds of structure (I). Particularly this invention is directed to compounds of structure (VIII) wherein the variables are defined as in the description. These compounds are integrin inhibitors and are useful in the treatment of diseases in which an inhibition of angiogenesis is desired.Type: ApplicationFiled: March 24, 2005Publication date: July 5, 2007Applicant: Jerini AGInventors: Grit Zahn, Roland Stragies, Frank Osterkamp, Gunther Zischinsky, Jochen Knolle, Gerd Hummel, Sascha Birkner, Ulrich Reineke
-
Publication number: 20060148716Abstract: The invention relates to novel peptides which are biologically active as ligands of blood platelet integrin GPIIbIIIa and the ?v integrins, preferably the ?v?s and ?v?3 integrin, having the formula (I): R1-Arg-X-Asp-Leu-Asp-Ser-Leu-Arg-R2 (I), in which R1 denotes H, acetyl or acyl and R2 denotes -Oh, OR3 NH2,NHR3, N(R3)2 R3 denotes atkyl, aralkyl, aryl, Het and X denotes an amino acid of the formula (II), in which A denotes (CH2)n R4 denotes H, alkyl, aralkyl or aryl, and n denotes 1, 2, 3, 4, 5 or 6, and the amino acid of the formula (II) is bonded to the adjacent Arg via a peptide bond of the ?-amino group and to the ?-amino group of the adjacent Asp via a peptide bond of the ?-carboxyl group.Type: ApplicationFiled: January 14, 2004Publication date: July 6, 2006Inventors: Alfred Jonczyk, Ulrich Groth, Gunther Zischinsky